Chelmsford, Massachusetts–based Zoll says it marks the fifth FDA-approved LifeVest WCD to hit the market. It works seamlessly with the company’s recently launched next-generation LifeVest WCD garment.

LifeVest delivers effective, safe therapy for patients at risk of sudden cardiac death. Zoll touts the highest rates of WCD patient compliance based on peer-reviewed publications and real-world data. It competes in a market that features WCDs from the likes of Kestra Medical and Element Science, among others.

New features for the latest LifeVest include greater comfort with lightweight, athleisure-inspired performance-wear fabric. It also has soft plush straps, flat-lock stitching and the largest range of garment sizes to fit a range of chest measurements.